Business Context and Reporting Period
This Form 8-K is filed by Histogenics Corporation (trading symbol: HSGX) on May 16, 2017. The filing addresses a regulatory notice received from The NASDAQ Stock Market LLC regarding the company's compliance with continued listing standards on The NASDAQ Global Market.
Key Financial Metrics
- Stockholders' Equity: Approximately $7.0 million as of March 31, 2017.
- Listing Requirement: Minimum stockholders' equity of $10.0 million required for The NASDAQ Global Market.
- Revenue, Profit, Cash Flow, Debt: The filing text does not provide specific values for revenue, profit, cash flow, margins, or debt levels.
Material Changes and Listing Status
The company received a notice indicating non-compliance with NASDAQ Marketplace Rule 5450(b)(1)(A) due to stockholders' equity falling below the $10.0 million threshold. This deficiency was reported in the Form 10-Q for the period ended March 31, 2017. The notice has no immediate effect on trading, and the stock continues to trade under the symbol "HSGX."
Outlook, Risks, and Management Commentary
- Compliance Timeline: The company has 45 calendar days (until June 30, 2017) to submit a plan to regain compliance. If accepted, an extension of up to 180 days (until November 12, 2017) may be granted to evidence compliance.
- Appeal Rights: If the plan is not accepted, the company retains the right to appeal, during which the stock would remain listed.
- Alternative Strategy: Management believes the company is eligible to transfer its listing to The NASDAQ Capital Market to maintain continued listing, provided it satisfies those specific requirements.
- Risks: There is no assurance the company will regain compliance or maintain listing. Delisting or failure to transfer could adversely affect the ability to sell equity securities and the liquidity of the common stock.
Investor Verification Checklist
- Verify the company's plan submission status to NASDAQ by the June 30, 2017 deadline.
- Confirm whether the company has initiated a transfer to The NASDAQ Capital Market.
- Review the most recent Form 10-Q (ended March 31, 2017) for detailed financial statements regarding the $7.0 million equity balance.
- Monitor for any updates on the appeal process if the initial compliance plan is rejected.